Analyst Group comments on Pharma Equity Group’s Positive Final Results From the Phase II Trial of the Drug Candidate RNX-051

Pharma Equity Group (“PEG” or “the Company”) announced on Friday, April 5th, that the Company’s subsidiary Reponex Pharmaceuticals A/S (“Reponex”) has received positive final results from the Phase II clinical proof-of-concept trial of the drug candidate RNX-051.

Länk till analysen i sin helhet: https://analystgroup.se/kommentarer/comment-on-pharma-equity-groups-positive-final-results-from-the-phase-ii-trial-of-the-drug-candidate-rnx-051/